219 results about "Recombinant antibodies" patented technology

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

The invention discloses a rapid detection method for traumatic brain injury by fusing genetic engineering and quantum dots, and relates to the technical field of traumatic brain injury detection. The method comprises the following steps: acquiring a suspected patient biological sample, extracting biomolecule components, and comparing the biomolecule components with a healthy population biomolecule database to obtain related differential expression molecules. A specifically recognizable recombinant antibody is constructed by genetic engineering, and is connected with a quantum dot through a coupling reaction to prepare a detection probe. The probe and a biological sample are mixed and reacted, and the intensity of a fluorescence signal generated by combination is collected by a fluorescence detection device. A standardized signal value is obtained through signal processing algorithm noise reduction and feature extraction, and a preliminary detection result is determined by combining a bioinformatics database evaluation sample. And finally, according to the differential expression molecule, the standardized signal value and the preliminary result, analyzing a data change trend in a preset time window by using a multivariable statistical model, and generating a diagnosis report. According to the method, various technologies are fused, and a new path is provided for traumatic brain injury detection.

Disclosed herein are recombinant antibodies or antigen binding fragments thereof that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the recombinant antibodies or antigen binding fragments thereof further comprise a CD3 binding domain.

The invention belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a mouse recombinant monoclonal antibody for specifically recognizing African horse pestivirus VP7 protein. According to the invention, a hybridoma cell strain 2C12 for African horse pestivirus VP7 protein is obtained through screening by using a hybridoma cell technology, total RNA is extracted and is subjected to reverse transcription to form cDNA, the cDNA is used as a template and is amplified by using a nested PCR method to obtain light chain and heavy chain variable region sequences of mouse IgG antibody molecules, the light chain and heavy chain variable region sequences are constructed to a plasmid vector containing a mouse source constant region, and the mouse IgG antibody is obtained. And co-transfecting 293F suspension cells for expression and purification to obtain the murine recombinant monoclonal antibody for specifically recognizing the African horse pestivirus VP7 protein. The recombinant antibody can specifically recognize the recombinant VP7 protein of the African horse plague virus, but does not recognize the recombinant VP7 protein of bluetongue virus and epidemic hemorrhagic fever virus, so that support is provided for further establishing a specific African horse plague diagnosis technology.

The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.

The invention belongs to the technical field of immunology, and provides a recombinant C-type single-domain nano antibody combined with CDH17 and application of the recombinant C-type single-domain nano antibody. According to the invention, an antibody with binding capacity to CDH17 is screened by using a phage display technology, then m01s is used as a skeleton recombinant antibody, and the C-type single-domain antibody with high affinity activity is obtained through antibody recombination. The obtained recombinant C-type single-domain nano antibody combined with CDH17 can be used as an indicator for diagnosis and prognosis of cancers, and is expected to become a candidate drug of CAR-T drugs for gastric cancer, breast cancer, colon cancer and the like due to high affinity to tumor cells.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

The present invention discloses an antibody targeting human Nectin4 protein and its application; the antibody comprises five groups of heavy chain variable regions and five groups of light chain variable regions, and the five groups of heavy chain variable region amino acid sequences can be combined with five groups of light chain variable region amino acid sequences for double chain use. The antibody can specifically recognize human Nectin4 antigen, and has good specificity in normal human tissues, only binds to Nectin4 positive tissues, does not recognize other tissues and organs, and has no off-target risk; at the same time, the antibody has good targeting for both natural configuration state and recombinant configuration state, and has good application prospects for antibody drugs, multi-antibody drugs and recombinant antibody proteins.

The present invention provides a recombinant antibody for Taq DNA polymerase, mainly involving recombinant antibodies whose heavy chain sequences and light chain sequences are derived from different species. The recombinant antibody provided by the present invention reduces nonspecific amplification products in PCR and qPCR reactions, improves the reaction accuracy and the stability of premixed reagents.

The present invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof that are specific for Factor H. The present invention also relates to the use of such antibodies and fragments for inhibiting complement activation and treating complement activation-related disorders.

Provided herein are methods and cell systems for production of a recombinant antibody in cells in which the antibody is directed against a target protein that is natively expressed as an intracellular protein in the cell. Also provided herein are modified cell lines for use in such methods in which the modified cell line is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

The utility model provides a recombinant antibody extraction device which comprises a box body and a reagent storage rack, an L-shaped positioning seat is fixed in the box body, the reagent storage rack is placed close to the L-shaped positioning seat, a rotating shaft is movably arranged in the box body, a pressing piece is fixed on the rotating shaft, a fixing ring seat is fixed outside the box body, and the fixing ring seat is fixed on the box body. One end of the rotating shaft penetrates through the box body and extends into the fixing ring base, a volute spiral spring is arranged in the fixing ring base, one end of the volute spiral spring is fixed to the rotating shaft, the other end of the volute spiral spring is fixed to the inner wall of the fixing ring base, a fixing block is fixed to the rotating shaft, a first check block is fixed to one side of the fixing block, and a second check block is fixed to the other side of the fixing block. The sample storage rack solves the problem that in the transportation process, if the storage box is knocked over, the sample storage rack is very easy to directly collide with the inner wall of the storage box, so that a reagent bottle is damaged.

This invention provides a wide range of neutralizing antibodies targeting the epitopes of human immunodeficiency virus (HVM) or HIV. Furthermore, it provides compositions containing antibodies for use in prevention, and methods for the diagnosis and treatment of HIV infection. [Solution] An isolated anti-HIV antibody or its antigen-binding fragment is provided, comprising a heavy chain variable region containing a specific sequence and a light chain variable region containing a specific sequence. The antibody is a recombinant antibody or a human antibody.

The present invention relates to a process for production and recovery of in-vivo refolded recombinant antibody fragment in a soluble form in the cytoplasm of a microbial expression system. More particularly, the present invention relates to a process for production of in-vivo refolded recombinant humanized biosimilar Ranibizumab antibody fragment in a soluble form in the cytoplasm of a microbial expression system. The present process provides an increased yield of the recombinant Ranibizumab accompanied with a reduction in overall manufacturing time for the production of rHu Ranibizumab in its native form to three days.

The invention relates to a specific antibody aiming at CD228 protein and an antigen binding fragment thereof, which are used for detecting and treating various tumors, such as melanoma, mesothelioma, colorectal cancer and the like. The antibody binding fragment is helpful for diagnosis and treatment of cancers through specific binding with CD228. The invention further comprises antibody drug conjugates (ADCs) which bind a drug to an antibody through a linker, so as to improve the therapeutic effect and reduce the influence on normal cells. Meanwhile, nucleic acids encoding the antibodies or antigen-binding fragments thereof are provided to produce recombinant antibodies or fragments. Besides, the invention also provides a kit which is used for laboratory research, clinical diagnosis and treatment effect monitoring, is beneficial to determining whether tissues or cells express CD228 or not, and provides a new strategy for personalized and precise treatment of cancers.

The present application relates to a 48E-scFv-Fc recombinant antibody with broad-spectrum activity against waterfowl parvovirus, a construction method and application thereof, the 48E-scFv-Fc recombinant antibody comprising a light chain variable region and a heavy chain variable region, and the amino acid sequences of the light chain variable region and the heavy chain variable region are shown as SEQ ID NO: 1-2. The present application provides a coding gene for encoding the recombinant antibody, which comprises a DNA sequence shown as SEQ ID NO: 3-4. The present application also provides a corresponding recombinant plasmid and a preparation method of the 48E-scFv-Fc recombinant antibody, etc. The 48E-scFv-Fc recombinant antibody can simultaneously recognize four waterfowl parvoviruses of cGPV, MDPV, MDGPV and SBDSV, and has a good application prospect in immunological detection of waterfowl parvovirus infection, antigen epitope research, passive immunization preparation development and broad-spectrum antibody drug research, etc.

The invention relates to the technical field of bioengineering, and aims to provide a CHO stably transfected cell strain capable of expressing a recombinant antibody capable of specifically recognizing CSFV2 type Erns protein. The cell strain is preserved in the China Center for Type Culture Collection, the preservation name is Chinese hamster ovary cell gs weak strain CHO-9B1-C, and the preservation number is CCTCC NO: C2024393. The invention also provides application of the cell strain in preparation of a diagnostic kit for specifically detecting the CSFV2 type hog cholera virus. The CHO stably transfected cell strain provided by the invention has the advantages of short monoclonal antibody production cycle, high consistency and high repeatability, is suitable for large-scale production, and is easy to transform.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

This invention belongs to the field of biochemical analysis technology, and discloses a magnetic bead for enriching tyrosine N-acetylgalactosamine modification sites, its preparation method, and its application. Specifically, it discloses a recombinant antibody, including the Fab fragment of a G10C antibody, the Fc region of an immunoglobulin, and an AviTag tag. This invention provides a recombinant antibody capable of specifically targeting and enriching tyrosine-O-GalNAc glycosylated peptides. By coupling this recombinant antibody to magnetic beads, the enrichment of tyrosine-O-GalNAc glycosylated peptides can be effectively improved, and interference and signal masking by glycosylation modifications on serine and threonine can be avoided, enabling the identification of more tyrosine glycosylation sites in a single sample.

This application relates to antibodies or combinations of antibodies or antigen¬ binding fragment(s) thereof that comprise a first binding unit that binds to a first epitope of a target protein that harbors a post-translational modification (PTM) and a second binding unit that binds to a second epitope of a target protein that does not harbor the PTM, as well as antibody fusion molecules and multispecific antibodies or antigen-binding fragments thereof that bind to same.

The present invention relates to: a recombinant polypeptide specifically binding to B cells; and a composition for preventing or treating B cell lymphoma, comprising same as an active ingredient. The present invention can significantly improve direct killing activity against tumor cells by conjugating concanavalin A, which is a ligand of MPZL1, to an antibody molecule that recognizes a B cell-specific antigen such as CD20. Therefore, unlike therapeutic antibodies having main mechanisms of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADP), the recombinant polypeptide of the present invention does not depend on operating mechanisms of patient immune systems, and thus can be effectively used in an effective therapeutic composition even for cancer patients with reduced immune activity.

The present invention relates to the field of antibodies, antigen-binding fragments and immunodiagnosis. Specifically, the present invention relates to recombinant antibodies or antigen-binding fragments for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Furthermore, the present invention relates to isolated nucleic acid molecules comprising nucleotide sequences encoding the recombinant antibodies or antigen-binding fragments of the present invention, as well as expression vectors and host cells comprising the nucleic acid molecules of the present invention. In addition, the present invention relates to methods for producing recombinant antibodies or antigen-binding fragments for binding T4 thyroid hormone and halogenated bisphenol A, test kits and immunoassays comprising the recombinant antibodies or antigen-binding fragments of the present invention, and methods for determining the levels of T4 thyroid hormone and / or halogenated bisphenol A in a sample of a subject. Furthermore, the present invention relates to methods for processing samples, such as immunoaffinity-based sample preparation methods for enriching halogenated bisphenol A from a sample.

Recombinant antibody T cell receptors (AbTCRs) and chimeric signaling receptors (CSRs) engineered to include antigen-binding domains specific for tumor antigen glypican-2 (GPC2) or glypican-3 (GPC3) are described. Immune cells expressing the AbTCRs and CSRs effectively treated GPC2-positive or GPC3-positive tumors in multiple different xenograft models, and were significantly more potent than similarly targeted chimeric antigen receptor (CAR) T cells.

The invention discloses a neutralizing antibody with an AQP3 channel blocking function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neutralizing antibody can be specifically combined with an extracellular domain of AQP3, after combination, a water channel and a small molecule transport function of the AQP3 are blocked through steric hindrance and conformation change, and meanwhile, antigen combination specificity is reserved. The preparation method is realized through'recombinant antigen-immunization-B cell screening culture-recombinant antibody expression and affinity purification-ELISA detection ', and the functions of the antibody are ensured. The antibody can be efficiently combined with AQP3 positive cells, is strong in targeting property and high in specificity (the serum titer reaches 1: 1024 * 10, and the purified antibody titer is greater than or equal to 1: 128 * 10), and can be independently used or combined with a nano-carrier for treating related diseases, so that the technical bottleneck that a common AQP3 antibody can only be combined and cannot efficiently play a blocking role is solved.

A high-mannose antibody-specific affinity material, a preparation method therefor and a use thereof. Provided are a lectin variant comprising (a) a histidine tag and (b) a cysteine-containing segment, added to the C-terminus of a reference lectin; a nucleic acid molecule encoding the lectin variant, and a vector and a cell containing the nucleic acid molecule; a composition and a matrix comprising the lectin variant; and a use of the lectin variant for reducing or removing a high-mannose antibody from a sample. The lectin variant has a specific affinity for high-mannose antibodies, and can effectively bind to high-mannose antibodies formed during antibody production, to remove high-mannose byproducts contained in recombinant antibodies, thereby effectively promoting and achieving required antibody purification in downstream stages of production.

Recombinant antibodies are provided that comprise engineered human IgG1 Fc domains that have reduced affinity for viral FcγRs, such as HCMV gp34 and gp68, as compared to a wild-type human IgG1 Fc domain. The engineered human IgG1 Fc domains have equivalent affinity for CD16A and FcRn as compared to a wild-type human IgG1 Fc domain. Also provided are engineered forms of HCMV gp34 and their use in a vaccine.

The invention belongs to the technical field of biochemical analysis, discloses a magnetic bead for enriching tyrosine N-acetylgalactosamine modification sites as well as a preparation method and application of the magnetic bead, and particularly discloses a recombinant antibody which comprises a Fab fragment of a G10C antibody, an immunoglobulin Fc region and an AviTag tag. The invention provides a recombinant antibody capable of enriching a tyrosine-O-GalNAc glycosylated peptide fragment in a specific targeting manner. By coupling the recombinant antibody to a magnetic bead, enrichment of tyrosine-O-GalNAc glycosylation peptide fragments can be effectively improved, interference and signal shielding of glycosylation modification on serine and threonine on site identification can be avoided, and more tyrosine glycosylation sites can be identified in a single sample.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The application provides an immune cell culture kit, a culture method and application of gamma delta T cells, and the kit comprises a basic culture medium, a recombinant antibody, a cytokine and a cell proliferation promoting additive, the basic culture medium comprises an RPMI-1640 culture medium, and the cell proliferation promoting additive comprises 1-thioglycerol, taurine, beta-cyclodextrin, thymidine, alpha-lipoic acid, beta-mercaptoethanol and bisphosphonate. The gamma delta T cells obtained by the culture kit have high purity and activity, and have good tumor killing activity. The gamma delta T cells obtained by the method have a high positive rate of 100% of perforin expression.

To provide a method for producing a recombinant antibody having a unique sugar chain spectrum from a genome-edited CHO host cell.SOLUTION: The method of the present invention is a method for editing fut8 genes in CHO cells suitable for suspension culturing in a serum free medium by TALEN technology, so that the edited CHO host cells can produce recombinant antibodies with unique glycan profiles. The unique glycan profile is characterized by having mainly non-fucosylated N-linked oligosaccharide chains, a low degree of heterogeneity of N-glycosylation, and uniform glycan chains. The antibodies prepared by the methods of the invention have increased ADCC activity and antibody stability.SELECTED DRAWING: Figure 10